Abstract: 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof is provided. Methods of treatment of bowl related disorders using isolated and/or purified 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof are also provided.
Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
Type:
Grant
Filed:
April 25, 2014
Date of Patent:
March 1, 2016
Assignee:
ALFA WASSERMANN S.P.A.
Inventors:
Giuseppe Claudio Viscomi, Manuela Campana, Donatella Confortini, Maria Barbanti, Dario Braga
Abstract: The present invention relates to a dry composition for reconstitution in water comprising polyethylene glycol (PEG), optionally sodium sulphate, citric acid, sodium citrate, sodium chloride, potassium chloride, simethicone, effective for bowel cleansing, in particular of colon, prior to diagnostic, surgical or therapeutical procedures, in particular colonoscopy.
Abstract: A centrifuge apparatus is provided that operates at certain predetermined parameters depending upon a product to be separated and is useable with a plurality of rotor assemblies. For example, a first rotor assembly of said plurality of rotor assemblies includes a first core having a first core configuration which is contained within a rotor housing of the first rotor assembly to define a first volume capacity such that the product passing through the first rotor assembly having the first volume capacity during rotation of the first rotor assembly in the centrifuge apparatus achieves a first particle separation of the product.
Type:
Grant
Filed:
November 30, 2010
Date of Patent:
June 9, 2015
Assignee:
Alfa Wassermann, Inc.
Inventors:
Sandra Patricia Merino, Steven J. Dalessio, Robin Roy Louis Rudy Otten
Abstract: 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof is provided. Methods of treatment of bowl related disorders using isolated and/or purified 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof are also provided.
Abstract: The present invention describes sulodexide or at least one of its components for use in the reduction of circulating matrix metalloproteinase (MMPs), in particular MMP-9. Sulodexide and its composition are useful for the treatment of pathologies wherein the MMPs are involved, such as cardiovascular disease, cardiovascular disease caused by diabetes, varicose veins, chronic venous insufficiency (CVI), gastrointestinal ulcers, pulmonary disease, and neoplastic pathologies.
Type:
Grant
Filed:
April 20, 2011
Date of Patent:
March 24, 2015
Assignee:
Alfa Wassermann S.p.A.
Inventors:
Giuseppe Claudio Viscomi, Ferdinando Mannello, Cristiana Bruno
Abstract: Disclosed herein are methods of treating a patient having an intestinal disorder, the methods comprising: administering to a patient in need thereof a pharmaceutical composition comprising a hydrate or solvate form of rifaximin in polymorphic form ?, alone or in a mixture with other crystalline, hydrate, solvate or amorphous forms of rifaximin, in gastroresistant microgranules, wherein the rifaximin is administered at a dose of at least 800 mg per day for a period of at least 7 days.
Type:
Application
Filed:
April 11, 2014
Publication date:
March 19, 2015
Applicant:
ALFA WASSERMANN S.P.A.
Inventors:
Giuseppe Claudio VISCOMI, Paola MAFFEI, Giuseppe BOTTONI, Maria GRIMALDI
Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
Type:
Application
Filed:
April 25, 2014
Publication date:
March 12, 2015
Applicant:
ALFA WASSERMANN S.P.A.
Inventors:
Giuseppe Claudio VISCOMI, Manuela CAMPANA, Donatella CONFORTINI, Maria Miriam BARBANTI, Dario BRAGA
Abstract: Polyols stabilize polymorphous form of rifaximin, in particular the ? form. When polyols having at least two hydroxy groups are added to rifaximin powder, polymorph ? is stable and remains stable in time independently from the environment humidity. In this invention a method to prepare formulations constituted by pure and stable polymorphous forms able to give a pharmaceutical product is described.
Type:
Application
Filed:
April 28, 2014
Publication date:
March 12, 2015
Applicant:
ALFA WASSERMANN S.P.A.
Inventors:
Paola MAFFEI, Milena BACHETTI, Giuseppe BOTTONI, Giuseppe Claudio VISCOMI
Abstract: Described herein are methods and systems for treatment and/or prevention of conditions associated with NSAID administration and related compositions.
Type:
Application
Filed:
April 11, 2014
Publication date:
October 16, 2014
Applicant:
ALFA WASSERMANN S.P.A.
Inventors:
Giuseppe Claudio VISCOMI, Maria GRIMALDI, Maria Vittoria FOGLI, Paola MAFFEI, Cecilia RENZULLI, Annalisa SFORZINI, Corrado BLANDIZZI, Carmelo SCARPIGNATO
Abstract: Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin ? and rifaximin ?, and a poorly crystalline form referred to as rifaximin ?, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.
Type:
Grant
Filed:
November 16, 2012
Date of Patent:
October 7, 2014
Assignee:
Alfa Wassermann S.p.A.
Inventors:
Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
Abstract: Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ?, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
Type:
Grant
Filed:
November 19, 2012
Date of Patent:
September 16, 2014
Assignee:
Alfa Wassermann S.p.A.
Inventors:
Giuseppe Claudio Viscomi, Manuela Campana, Dario Braga, Donatella Confortini, Vincenzo Cannata, Paolo Righi, Goffredo Rosini
Abstract: An automated liquid collection workstation is provided. The workstation includes a processor, a peristaltic pump, a valve actuator, and an algorithm. The peristaltic pump and the valve actuator are in electrical communication with the processor. The valve actuator can move a plurality of valves, when disposed therein, among an off position, a flush position, and a collection position. The algorithm is resident on the processor and is configured to: move all of the valves to the off position and place the pump in an off state when no sampling or flushing is required, move all of the valves to the flush position and place the pump in an on state for a predetermined flush time period when flushing is required, and move a respective one of the valves to the collection position, move any of the valves upstream of the respective valve to the flush position, and place the pump to the on state for a predetermined collection time period when collection is required.
Abstract: The present invention describes rifaximin powder and to a process for preparing the same. The invention relates also to a pharmaceutical composition in solid form comprising said rifaximin, pharmaceutically acceptable excipients and optionally other ingredients. The compositions according to the invention are suitable for oral administration and are characterized by producing a controlled release of rifaximin, whereby a long-lasting effect is obtained in a patient.
Type:
Application
Filed:
April 24, 2014
Publication date:
August 21, 2014
Applicant:
ALFA WASSERMANN S.P.A.
Inventors:
Giuseppe Claudio VISCOMI, Paola MAFFEI, Vittoria LAURO, Miriam BARBANTI, Donatella CONFORTINI, Dario BRAGA
Abstract: The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.
Type:
Application
Filed:
December 4, 2013
Publication date:
July 3, 2014
Applicant:
ALFA WASSERMANN S.P.A.
Inventors:
Giuseppe Claudio VISCOMI, Ernesto PALAZZINI, Villiam ZAMBONI, Maria Rosaria PANTALEO
Abstract: Disclosed are rifamycin derivatives having antibacterial activities, wherein the compounds have the following general formula: wherein: R is hydrogen or acetyl; R1 and R2 are independently selected from the group consisting of hydrogen, (C1-4) alkyl, benzyloxy, mono- and di-(C1-3) alkylamino-(C1-4)alkyl, (C1-3)alkoxy, (C1-4) alkyl, hydroxy-methyl, hydroxy-(C2-4)-alkyl, and nitro or R1 and R2 taken together with two consecutive carbon atoms of the pyridine nucleus form a benzene ring optionally substituted by one or two methyl or ethyl groups and R3 is hydroxyalkyl (C1-4). In addition, processes to obtain these compounds are described.
Type:
Grant
Filed:
November 26, 2012
Date of Patent:
July 1, 2014
Assignee:
Alfa Wassermann S.p.A.
Inventors:
Giuseppe Glaudio Viscomi, Manuela Campana, Mahena Folegatti, Paolo Righi, Vincenzo Cannata, Goffredo Rosini
Abstract: Polyols stabilize polymorphous form of rifaximin, in particular the ? form. When polyols having at least two hydroxy groups are added to rifaximin powder, polymorph ? is stable and remains stable in time independently from the environment humidity. In this invention a method to prepare formulations constituted by pure and stable polymorphous forms able to give a pharmaceutical product is described.
Type:
Grant
Filed:
July 9, 2012
Date of Patent:
June 10, 2014
Assignee:
Alfa Wassermann S.p.A.
Inventors:
Paola Maffei, Milena Bachetti, Giuseppe Bottoni, Giuseppe Claudio Viscomi
Abstract: The present invention describes rifaximin powder and to a process for preparing the same. The invention relates also to a pharmaceutical composition in solid form comprising said rifaximin, pharmaceutically acceptable excipients and optionally other ingredients. The compositions according to the invention are suitable for oral administration and are characterized by producing a controlled release of rifaximin, whereby a long-lasting effect is obtained in a patient.
Type:
Grant
Filed:
March 4, 2011
Date of Patent:
June 10, 2014
Assignee:
Alfa Wassermann S.p.A.
Inventors:
Giuseppe Claudio Viscomi, Paola Maffei, Vittoria Lauro, Miriam Barbanti, Donatella Confortini, Dario Braga
Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
Type:
Grant
Filed:
July 25, 2013
Date of Patent:
June 3, 2014
Assignee:
Alfa Wassermann S.p.A.
Inventors:
Giuseppe Claudio Viscomi, Manuela Campana, Donatella Confortini, Maria Barbanti, Dario Braga